Low Tumor Infiltrating Mast Cell Density Reveals Prognostic Benefit in Cervical Carcinoma

Autor: Fan Guo PhD, Wei-Na Kong MM, De-Wei Li MM, Gang Zhao MM, Hui-Li Wu MM, Miyessar Anwar MM, Xiao-Qian Shang MM, Qian-Nan Sun MM, Cai-Ling Ma PhD, Xiu-Min Ma PhD

Publikováno v: Technology in Cancer Research & Treatment, Vol 21 (2022)

Objectives: Research on the role of mast cells (MCs) in cervical tumor immunity is more limited. Therefore, our study aimed to evaluate the prognostic value of MCs and their correlation with the immune microenvironment of cervical carcinoma (CC). Met

Externí odkaz: https://doaj.org/article/634381dbfc1e449485074562f32fc5e6

Expert consensus on the use of omalizumab in chronic urticaria in China

Autor: Zuotao Zhao, MD, PhD, Tao Cai, MD, Hong Chen, MD, Liuqing Chen, MD, Yudi Chen, MD, Xiang Gao, MD, Xinghua Gao, MD, Songmei Geng, MD, Yinshi Guo, MD, Fei Hao, MD, Guodong Hao, MM, Yan Hu, MD, Hongzhong Jin, MD, Zhehu Jin, MD, Chengxin Li, MD, Haili Li, MD, Jie Li, MD, Yanming Li, MD, Yunsheng Liang, MD, Guanghui Liu, MD, Qiang Liu, MD, Hai Long, MD, Lin Ma, MD, Yuanyuan Shang, MM, Yuxin Song, MB, Zhiqiang Song, MD, Xiangyang Su, MD, Haijing Sui, MD, Qing Sun, MD, Yuemei Sun, MB, Jianping Tang, MD, Xunliang Tong, MD, Huiying Wang, MD, Gang Wang, MD, Lianglu Wang, MD, Siqin Wang, MB, Li Xiang, MD, Ting Xiao, MD, Zhiqiang Xie, MD., Leping Ye, MD, Yongmei Yu, MM, Chunlei Zhang, MD, PhD, Litao Zhang, MD, Shuchen Zhang, MD, PhD, Rui Zheng, MD, Lili Zhi, MM, Wei Zhou, MD, Ying Zou, MD, Marcus Maurer, MD

Publikováno v: World Allergy Organization Journal, Vol 14, Iss 11, Pp 100610- (2021)

Chronic urticaria (CU) is a debilitating skin disease that lasts for more than 6 weeks with wheals and/or angioedema, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). In China, the prevalence of this disease is h

Externí odkaz: https://doaj.org/article/9875079723964e719a0bcd96761f2778

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Identifying novel B-cell targets for chronic inflammatory autoimmune disease by screening of chemical probes in a patient-derived cell assay.

Autor: Sundström Y; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Shang MM; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Panda SK; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Grönwall C; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Wermeling F; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Gunnarsson I; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Lundberg IE; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Sundström M; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Jakobsson PJ; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Berg L; Division of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden. Electronic address: louise.berg@ki.se.

Publikováno v: Translational research : the journal of laboratory and clinical medicine [Transl Res] 2021 Mar; Vol. 229, pp. 69-82. Date of Electronic Publication: 2020 Sep 22.

Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E 2 Production.

Autor: Bergqvist F; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.; The Structural Genomic Consortium (SGC), Karolinska Institutet, Stockholm, Sweden., Sundström Y; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.; The Structural Genomic Consortium (SGC), Karolinska Institutet, Stockholm, Sweden., Shang MM; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.; The Structural Genomic Consortium (SGC), Karolinska Institutet, Stockholm, Sweden., Gunnarsson I; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden., Lundberg IE; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden., Sundström M; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.; The Structural Genomic Consortium (SGC), Karolinska Institutet, Stockholm, Sweden., Jakobsson PJ; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.; The Structural Genomic Consortium (SGC), Karolinska Institutet, Stockholm, Sweden., Berg L; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.; The Structural Genomic Consortium (SGC), Karolinska Institutet, Stockholm, Sweden.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2020 May 06; Vol. 11, pp. 613. Date of Electronic Publication: 2020 May 06 (Print Publication: 2020).